Pilot Study of the Use of Functional Near-Infrared Spectroscopy (fNIRS) Combined With Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical Controls

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background: Neurocognitive disorders affect how the brain uses oxygen. They may affect mental development in children. These disorders can be studied with imaging scans that use radiation; however, these methods are not ideal for research on children. Two technologies-functional near-infrared spectroscopy (fNIRS) and diffuse correlation spectroscopy (DCS)-use light to detect changes in brain activity. These methods are safer, and they can be used in a more relaxed setting. In this natural history study, researchers want to find out whether fNIRS and DCS can be a good way to study people with neurocognitive disorders.

Objective: To find out whether fNIRS and DCS can be useful in measuring brain activity in people with neurocognitive disorders.

Eligibility: People aged 6 months or older with neurocognitive disorders. These can include Niemann-Pick disease type C1 (NPC1); creatine transporter deficiency (CTD); Smith Lemli Opitz syndrome (SLOS); juvenile neuronal ceroid lipofuscinosis (CLN3 disease); and Pheland-McDermid (PMS) syndrome. Healthy volunteers are also needed.

Design: Participants will have a physical exam. They will have tests of their memory and thinking. Participants will sit in a quiet room for the fNIRS and DCS tests. A snug cap (like a cloth swim cap) will be placed on their head. The cap has lights and sensors. Another sensor will be placed on their forehead. Participants will perform tasks on a computer. This testing will take 45 to 60 minutes. The tests will be repeated within 1 to 4 weeks. Participants will be asked to return for repeat tests 1 year later....

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6 months
Maximum Age: 110
Healthy Volunteers: t
View:

• For both study populations (Affected and Typically Developing group):

‣ Male or female, aged 6 months and up

⁃ English is the primary language spoken at home

• For study population (Affected group):

⁃ -Neurocognitive-related conditions including SLOS, CLN3, CTD, NPC and PMS.

• For controls (Typically Developing Group):

‣ In good general health as determined by medical history and physical exam

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Samar N Rahhal, M.D.
rahhalsn@nih.gov
(202) 468-1716
Time Frame
Start Date: 2023-01-23
Estimated Completion Date: 2026-03-01
Participants
Target number of participants: 100
Treatments
1
individuals without known health or medical issues (i.e. healthy volunteers)
2
individuals with known neurocognitive disorders (i.e. affected)
Sponsors
Leads: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

This content was sourced from clinicaltrials.gov